Allschwil, Switzerland, February 05, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that the sales of the antifungal Cresemba® (isavuconazole) in Japan exceeded the threshold triggering the first sales milestone payment from its partner Asahi Kasei Pharma (AKP), amounting to approximately CHF 1.2 million. David Veitch, Chief Executive Officer of Basilea ...

Nasdaq CopenhagenLondon Stock ExchangeEuronext DublinOther stakeholders 5 February 2025 Ringkjøbing Landbobank’s annual report for 2024 The bank’s board of directors and general management today approved the annual report for 2024. For 2024, a net profit at the top of the announced expectations for the year is realized with DKK 2,301 million, corresponding to an increase of 7% compared to 2023. The bank is very satisfied with this development. Core earnings (DKK million)20242023202220212020Total core inco ...

Regulated information Intermediate declaration by the Board of Directors Ieper, Belgium - February 5th, 2025, 07.00 hrs CET Dear, Please find herewith the link to our most recent press release: https://www.melexis.com/en/news/2025/financial/melexis-q4-2024-results Attachment PR_ENG_Melexis_Q4 2024 ...

CONTINUED STRONG EARNINGS MOMENTUM IN 2024 CASA AND CAG STATED AND UNDERLYING DATA Q4-2024 CRÉDIT AGRICOLE S.A. CRÉDIT AGRICOLE GROUP Stated Underlying Stated Underlying <td style="width:104.2px;;border-top: solid black 1pt ...

Saint Herblain (France), February 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for the world’s first and only chikungunya vaccine, IXCHIQ®. The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older. The vaccine is ...

MONTREAL, Feb. 05, 2025 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) announced today that the Company’s 2024 Annual Financial Statements, Notes thereto and Management’s Discussion and Analysis, and its 2024 Annual Information Form and Form 40-F, have been filed with Canadian and U.S. securities regulators and are now available in the “Investors” section of its website, www.cn.ca/investors. Printed copies of CN’s 2024 Annual Financial Statements, Notes thereto and Management’s Discussion and Analysis will a ...

Saint Herblain (France), February 5, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for the world's first and only chikungunya vaccine, IXCHIQ®. The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older. The vaccine is manufactur ...

MONTREAL, Feb. 05, 2025 (GLOBE NEWSWIRE) -- CN (TSX:CNR) (NYSE:CNI) announced today that the Company's 2024 Annual Financial Statements, Notes thereto and Management's Discussion and Analysis, and its 2024 Annual Information Form and Form 40-F, have been filed with Canadian and U.S. securities regulators and are now available in the "Investors" section of its website, www.cn.ca/investors. Printed copies of CN's 2024 Annual Financial Statements, Notes thereto and Management's Discussion and Analysis will als ...

Equinor (OSE: EQNR, NYSE: EQNR) will on 6 February 2025 commence the first tranche of up to USD 1.2 billion of the share buy-back programme for 2025, as announced at the Capital Market Update 5 February 2025. In this first tranche, shares for up to USD 396 million will be purchased in the market, implying a total first tranche of up to USD 1.2 billion including shares to be redeemed from the Norwegian State. The tranche will end no later than 2 April 2025. Equinor announces a share buy-back programme of up ...

Key information relating to the proposed cash dividend to be paid by Equinor (OSE: EQNR, NYSE: EQNR) for fourth quarter 2024. Cash dividend amount: 0.37 Announced currency: USD Last day including rights: 14 May 2025 Ex-date Oslo Børs: 15 May 2025 Ex-date New York Stock Exchange: 16 May 2025 Record date: 16 May 2025 Payment date: 28 May 2025 Date of approval: the proposed cash dividend is subject to approval by the annual general meeting of Equinor ASA on 14 May 2025. Other information: The cash dividend per ...